Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
2,3-Dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143; IMPY) inhibits partially purified ribonucleotide reductase from Ehrlich tumor cells. Both cytidine 5'-diphosphate and adenosine 5'-diphosphate reductase activities were inhibited by IMPY, although adenosine 5'-diphosphate reductase activity was inhibited to a greater extent than was cytidine 5'-diphosphate reductase activity at all concentrations of IMPY studied. The inhibition of the intact enzyme by IMPY could be reversed by the addition of the exogenous non-heme iron-containing subunit (tris(hydroxymethyl)aminomethane fraction) but not by the addition of the effector-binding subunit. Further, the inhibition of the intact enzyme or the tris(hydroxymethyl)aminomethane fraction by IMPY could be reversed by the addition of 6 microM Fe(NH4)2(SO4)2, and the inhibition of IMPY could be potentiated by 0.167 mM ethylenediaminetetraacetic acid. These results demonstrate that IMPY inhibits tumor cell nucleotide reductase by interaction with the iron of the non-heme iron-containing subunit.
D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology*; D003565:Cytidine Diphosphate / Q000378:metabolism; D004347:Drug Interactions; D004492:Edetic Acid / Q000494:pharmacology; D005296:Ferrous Compounds / Q000494:pharmacology; D006418:Heme / Q000037:antagonists & inhibitors; D046911:Macromolecular Substances; D051379:Mice; D011720:Pyrazoles / Q000494:pharmacology*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013379:Substrate Specificity
D005296:Ferrous Compounds; D046911:Macromolecular Substances; D011720:Pyrazoles; C026262:imidazopyrazole; D006418:Heme; D000244:Adenosine Diphosphate; D003565:Cytidine Diphosphate; D004492:Edetic Acid; D012264:Ribonucleotide Reductases